Literature DB >> 26384594

Application and Dosimetric Requirements for Gallium-68-labeled Somatostatin Analogues in Targeted Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors.

David Taïeb1, Philippe Garrigue2, Manuel Bardiès3, Ahmad Esmaeel Abdullah4, Karel Pacak5.   

Abstract

Neuroendocrine tumors (NETs) are associated with variable prognosis, with grade 1 and 2 NETs having more favorable outcomes than grade 3. Patients with gastroenteropancreatic (GEP)-NET need individualized interdisciplinary evaluations and treatment. New treatment options have become available with significant improvements in progression-free survival. Peptide receptor radionuclide therapy (PRRT) using (90)Y or (177)Lu-labeled somatostatin analogues (SSTa) has also shown promise in the treatment of advanced progressive NETs. (68)Ga-1,4,7,10-tetraazacyclodecane-1,4,7,10-tetraacetic acid (DOTA)-SSTa can be used as companion imaging agents to assist in radionuclide therapy selection. (68)Ga-DOTA-SSTa PET/computed tomography might also provide information for prognosis, tumor response assessment to PRRT, and internal dosimetry.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Gallium radioisotopes; Gastroenteropancreatic; Neuroendocrine; PET; Somatostatin

Mesh：

Substances：

Year:  2015        PMID： 26384594      PMCID： PMC4617555          DOI： 10.1016/j.cpet.2015.06.001

Source DB:  PubMed          Journal:  PET Clin        ISSN： 1556-8598


  46 in total

1.  68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors.

Authors:  Alexander R Haug; Christoph J Auernhammer; Björn Wängler; Gerwin P Schmidt; Christopher Uebleis; Burkhard Göke; Paul Cumming; Peter Bartenstein; Reinhold Tiling; Marcus Hacker
Journal:  J Nucl Med       Date:  2010-08-18       Impact factor: 10.057

2.  68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5.

Authors:  Damian Wild; Helmut R Mäcke; Beatrice Waser; Jean Claude Reubi; Mihaela Ginj; Helmut Rasch; Jan Müller-Brand; Michael Hofmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-06       Impact factor: 9.236

3.  Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use.

Authors:  J C Reubi; J C Schär; B Waser; S Wenger; A Heppeler; J S Schmitt; H R Mäcke
Journal:  Eur J Nucl Med       Date:  2000-03

4.  Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship.

Authors:  Raffaella Barone; Françoise Borson-Chazot; Roelf Valkema; Stéphan Walrand; Franck Chauvin; Lida Gogou; Larry K Kvols; Eric P Krenning; François Jamar; Stanislas Pauwels
Journal:  J Nucl Med       Date:  2005-01       Impact factor: 10.057

5.  Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.

Authors:  Christian Waldherr; Miklos Pless; Helmut R Maecke; Tilmann Schumacher; Armin Crazzolara; Egbert U Nitzsche; Andreas Haldemann; Jan Mueller-Brand
Journal:  J Nucl Med       Date:  2002-05       Impact factor: 10.057

6.  Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy.

Authors:  Samer Ezziddin; Martin Opitz; Mared Attassi; Kim Biermann; Amir Sabet; Stefan Guhlke; Holger Brockmann; Winfried Willinek; Eva Wardelmann; Hans-Jürgen Biersack; Hojjat Ahmadzadehfar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-09-18       Impact factor: 9.236

7.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

Authors:  Eric Raymond; Laetitia Dahan; Jean-Luc Raoul; Yung-Jue Bang; Ivan Borbath; Catherine Lombard-Bohas; Juan Valle; Peter Metrakos; Denis Smith; Aaron Vinik; Jen-Shi Chen; Dieter Hörsch; Pascal Hammel; Bertram Wiedenmann; Eric Van Cutsem; Shem Patyna; Dongrui Ray Lu; Carolyn Blanckmeister; Richard Chao; Philippe Ruszniewski
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

8.  DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals.

Authors:  Damian Wild; Jörg S Schmitt; Mihaela Ginj; Helmut R Mäcke; Bert F Bernard; Eric Krenning; Marion De Jong; Sandra Wenger; Jean-Claude Reubi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-08-21       Impact factor: 9.236

Review 9.  Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.

Authors:  E P Krenning; D J Kwekkeboom; W H Bakker; W A Breeman; P P Kooij; H Y Oei; M van Hagen; P T Postema; M de Jong; J C Reubi
Journal:  Eur J Nucl Med       Date:  1993-08

10.  Quantitation in PET using isotopes emitting prompt single gammas: application to yttrium-86.

Authors:  Stéphan Walrand; François Jamar; Isabelle Mathieu; Joëlle De Camps; Max Lonneux; Mérence Sibomana; Daniel Labar; Christian Michel; Stanislas Pauwels
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-12-17       Impact factor: 9.236
View more
  3 in total

Review 1.  Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups.

Authors:  David Taïeb; Abhishek Jha; Giorgio Treglia; Karel Pacak
Journal:  Endocr Relat Cancer       Date:  2019-11       Impact factor: 5.678

Review 2.  Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment.

Authors:  Hossein Jadvar
Journal:  AJR Am J Roentgenol       Date:  2017-05-02       Impact factor: 3.959

Review 3.  Current Management of Pheochromocytoma/Paraganglioma: A Guide for the Practicing Clinician in the Era of Precision Medicine.

Authors:  Svenja Nölting; Martin Ullrich; Jens Pietzsch; Christian G Ziegler; Graeme Eisenhofer; Ashley Grossman; Karel Pacak
Journal:  Cancers (Basel)       Date:  2019-10-08       Impact factor: 6.639
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.